Carbetocin intranasal - Ferring Pharmaceuticals

Drug Profile

Carbetocin intranasal - Ferring Pharmaceuticals

Alternative Names: FE-992097

Latest Information Update: 04 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Oxytocics; Posterior pituitary hormones
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prader-Willi syndrome
  • Phase I Obesity

Most Recent Events

  • 27 Oct 2016 Carbetocin intranasal licensed to Levo Therapeutics worldwide
  • 19 Apr 2016 Phase-II development for Prader-Willi syndrome is ongoing in USA
  • 01 Jul 2014 Ferring Pharmaceuticals completes a phase II trial in Prader-Willi syndrome (hyperphagia) in USA (NCT01968187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top